Edurant™ 96-Week Phase 3 safety and efficacy data presented
19 July 2011 | By Janssen Therapeutics
Janssen Therapeutics, presented 96-week findings from two pivotal Phase 3 clinical trials...
List view / Grid view
News
Millennium submits supplemental new drug application with FDA
19 July 2011 | By Takeda Pharmaceutical Company Limited
Millennium announced the submission of a supplemental New Drug Application (sNDA) with the U.S. FDA for VELCADE® (bortezomib)...
Lilly presents follow-up data on semagacestat to assist future Alzheimer’s disease research
19 July 2011 | By Eli Lilly and Company
Data presented from the first of two Phase III trials of semagacestat...
Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing
19 July 2011 | By Roche
Roche has signed an agreement to acquire 100% of mtm laboratories AG (mtm)...
Florbetapir “Imaging to Autopsy” study awarded Alzheimer’s Association’s 2011 de Leon Prize in Neuroimaging
18 July 2011 | By Eli Lilly and Company
Winner of the 2011 de Leon Prize in Neuroimaging...
VICTRELIS™ (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union
18 July 2011 | By Merck
The European Commission approved VICTRELIS™ (boceprevir)...
New data showed minimal potential for drug interaction between cholesterol drug LIVALO® and a common antiretroviral therapy
18 July 2011 | By Eli Lilly and Company
New study results released...
Merck’s ISENTRESS® (raltegravir) in combination therapy demonstrated efficacy in a Phase II Study
18 July 2011 | By Merck
Extending to nearly five years in previously untreated adults with HIV-1...
Amgen resolves G-CSF patent litigation With Teva
15 July 2011 | By Amgen
Amgen announced that the U.S. District Court in Pennsylvania has entered final judgment and a permanent injunction against TEVA...
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
15 July 2011 | By Amgen
The European Commission has granted marketing authorization for XGEVA® (denosumab)...
Abbott confirms long-term commitment to HIV care with the planned development of new formulations
15 July 2011 | By Abbott
Abbott plans to develop two new formulations of its HIV medicines...
Novartis begins shipment of Fluvirin®
15 July 2011 | By Novartis
Novartis announced that the Company has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season...
Janssen Pharmaceuticals, Inc. announces definitive agreement to divest Ortho Dermatologics Division
15 July 2011 | By Janssen Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc. announced a definitive agreement to divest the assets of its Ortho Dermatologics division...
Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse
15 July 2011 | By Roche
Roche plans to seek approval with Health Authorities based on encouraging results...
ICON acquires Firecrest Clinical
14 July 2011 | By ICON plc
ICON plc, announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management...
